Needham Reiterates Buy on RxSight, Maintains $34 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst David Saxon has reiterated a 'Buy' rating on RxSight (NASDAQ:RXST) and maintained a price target of $34.
August 08, 2023 | 9:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst David Saxon has reiterated a 'Buy' rating on RxSight and maintained a price target of $34.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $34 price target indicates a positive outlook for RxSight. This could potentially lead to an increase in investor confidence and a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100